Topicals, generic [Regulatives / Guidelines]

posted by The Outlaw Torn – Europe, 2013-04-01 10:03 (4463 d 21:35 ago) – Posting: # 10319
Views: 25,748

Good morning folks,

It seems the new guideline hasn't removed the need to conduct a BE study (for safety reasons) for opthalmic solutions that may contain an ingredient that is absorbed systemically. Has anyone successfully argued against this? It appears it's still fine to obtain a biowaiver for the efficacy part, but not for safety?! To me, this is a WTF moment, but maybe I'm missing out on something. Does that make sense to anyone (for a solution)?

Thank you,
Outlaw

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,673 registered users;
79 visitors (0 registered, 79 guests [including 50 identified bots]).
Forum time: 07:38 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5